{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T22:55:41Z","timestamp":1752101741614},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T00:00:00Z","timestamp":1512432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10792-017-0773-2","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T05:19:10Z","timestamp":1512451150000},"page":"2593-2597","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of locally produced Latanoprost in the control of intraocular pressure in patients with primary open-angle glaucoma"],"prefix":"10.1007","volume":"38","author":[{"given":"Pir Salim","family":"Mahar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeem H.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Imtiaz","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,5]]},"reference":[{"key":"773_CR1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/exer.1998.0508","volume":"67","author":"A Ocklind","year":"1998","unstructured":"Ocklind A (1998) Effect of Latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 67:179\u2013191","journal-title":"Exp Eye Res"},{"key":"773_CR2","first-page":"1514","volume":"42","author":"JW Kim","year":"2001","unstructured":"Kim JW, Lindsey JD, Wang N et al (2001) Increased human sclera permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 42:1514\u20131521","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"773_CR3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1034\/j.1600-0420.2001.790604.x","volume":"79","author":"LI Larsson","year":"2001","unstructured":"Larsson LI (2001) Intraocular pressure over 24 hours after single-dose administration of Latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand 79:567\u2013571","journal-title":"Acta Ophthalmol Scand"},{"key":"773_CR4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0161-6420(96)30749-5","volume":"103","author":"CB Camras","year":"1996","unstructured":"Camras CB (1996) Comparison of Latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138\u2013147","journal-title":"Ophthalmology"},{"key":"773_CR5","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0161-6420(95)30798-1","volume":"102","author":"A Aml","year":"1995","unstructured":"Aml A, Stjernschantz J (1995) Effects on intraocular pressure and side effects of 0.005% Latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743\u20131752","journal-title":"Ophthalmology"},{"key":"773_CR6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0161-6420(96)30750-1","volume":"103","author":"P Watson","year":"1996","unstructured":"Watson P, Stjernschantz J (1996) A six-month randomized, double-masked study comparing Latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 103:126\u2013137","journal-title":"Ophthalmology"},{"key":"773_CR7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0039-6257(02)00301-6","volume":"47","author":"K Hedman","year":"2002","unstructured":"Hedman K, Watson P, Alm A (2002) The effect of Latanoprost on Intraocular pressure during 2\u00a0years of treatment. Survey Ophthalmol 47:65\u201375","journal-title":"Survey Ophthalmol"},{"issue":"1","key":"773_CR8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5301\/ejo.5000041","volume":"22","author":"C Allauire","year":"2012","unstructured":"Allauire C, Dietrich A, Allmeir H, Grundmane I, Mazur-Piotrowska G, Kahle G (2012) Latanoprost 0.005%, test formulation is as effective as Xalatan in patients with ocular hypertension and primary open angle glaucoma. Eur J Ophthalmol 22(1):19\u201327","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"773_CR9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/1440-1681.12329","volume":"42","author":"S Golan","year":"2015","unstructured":"Golan S, Rosenfeld E, Shemesh G, Kurtz S (2015) Original and generic Latanoprost for the treatment of glaucoma and ocular hypertension are really the same? Clin Exp Pharmacol Physiol 42(2):220\u2013224","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"9","key":"773_CR10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/IJG.0b013e318259b47c","volume":"22","author":"M Digiuni","year":"2013","unstructured":"Digiuni M, Manni G, Vetrugno M, Uva M, Milano G, Orzalesi N et al (2013) An evaluation of therapeutic non-inferiority of 0.005% Latanoprost ophthalmic solution and Xalatan in patients with glaucoma or ocular hypertension. J Glaucoma 22(9):707\u2013712","journal-title":"J Glaucoma"},{"issue":"3","key":"773_CR11","first-page":"11","volume":"24","author":"M Hashemi","year":"2012","unstructured":"Hashemi M, Miraftabi A, Nilforoushan N, Ghasemi Falaranjani K, Pakdel F, Soudi R et al (2012) Comparison of the efficacy and tolerability of Xalatan and Xalabiost (Generic Latanoprost) in adults with open angle glaucoma and ocular hypertension. A two-center, randomized crossover trial. Iran J Ophthalmol 24(3):11\u201318","journal-title":"Iran J Ophthalmol"},{"issue":"2","key":"773_CR12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/0301-4738.30707","volume":"55","author":"A Narayanaswamy","year":"2007","unstructured":"Narayanaswamy A, Neog A, Baskaran M, Gewge R, Lingham V, Desai C, Rajadhyaksha V (2007) A randomized crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with gerneric Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol 55(2):127\u2013131","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"773_CR13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/108076802760116205","volume":"18","author":"WJ Scherer","year":"2004","unstructured":"Scherer WJ (2004) A retrospective review of non-responders to Latanoprost. J Ocular Pharmacol Ther 18(3):287\u2013291","journal-title":"J Ocular Pharmacol Ther"},{"issue":"2","key":"773_CR14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10384-005-0293-x","volume":"50","author":"Y Ikeda","year":"2006","unstructured":"Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S (2006) Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jap J Ophthalmol 50(2):153\u2013157","journal-title":"Jap J Ophthalmol"},{"issue":"3","key":"773_CR15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.ijg.0000212214.18018.41","volume":"15","author":"L Rossetti","year":"2006","unstructured":"Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G et al (2006) An evaluation of the rate of non-responders to Latanoprost therapy. J Glaucoma 15(3):238\u2013243","journal-title":"J Glaucoma"},{"issue":"4","key":"773_CR16","doi-asserted-by":"crossref","first-page":"738747","DOI":"10.1016\/j.ophtha.2014.11.022","volume":"122","author":"JD Stein","year":"2015","unstructured":"Stein JD, Shekhawat N, Talwar N, Balkrishnan R (2015) Importance of the introduction of generic Latanoprost on glaucoma medication adherence. Ophthalmol 122(4):738747","journal-title":"Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-017-0773-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-017-0773-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-017-0773-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T22:50:46Z","timestamp":1543445446000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-017-0773-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,5]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1007\/s10792-017-0773-2","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,5]]}}}